Guggenheim began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued to investors on Monday, September 17th, The Fly reports. The brokerage issued a buy rating on the biotechnology company’s stock.
A number of other research analysts also recently issued reports on ADAP. BidaskClub downgraded Adaptimmune Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 4th. ValuEngine raised Adaptimmune Therapeutics from a buy rating to a strong-buy rating in a research report on Monday, July 2nd. Cowen reissued a buy rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, July 18th. TheStreet cut Adaptimmune Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 16th. Finally, Leerink Swann increased their price target on Adaptimmune Therapeutics to $20.00 and gave the company an outperform rating in a research report on Monday, June 4th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $19.33.
Shares of Adaptimmune Therapeutics stock traded down $0.20 during trading hours on Monday, hitting $12.41. The company’s stock had a trading volume of 466,897 shares, compared to its average volume of 496,185. Adaptimmune Therapeutics has a 12 month low of $6.60 and a 12 month high of $14.63. The company has a market capitalization of $1.28 billion, a P/E ratio of -15.51 and a beta of 1.06.
In other Adaptimmune Therapeutics news, Director Ali Behbahani acquired 12,000,000 shares of the business’s stock in a transaction dated Friday, September 7th. The stock was bought at an average cost of $1.67 per share, with a total value of $20,040,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $10.25, for a total value of $256,250.00. The disclosure for this sale can be found here. Company insiders own 26.47% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $122,000. BB&T Securities LLC acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $128,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of Adaptimmune Therapeutics by 70.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 13,151 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at approximately $168,000. Finally, Trexquant Investment LP acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at approximately $178,000. 59.32% of the stock is owned by institutional investors.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Further Reading: Buyback For Investors Defined
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.